This inventor holds 2 USPTO granted patents. Top assignee: Nanjing Kaedi Biotherapeutics Ltd.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Innovations of Jingjing Zhu in Cancer Treatment
Introduction
Jingjing Zhu is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of biotherapeutics, particularly in the development of chimeric antigen receptor (CAR) cells for cancer treatment. With a total of 2 patents, his work focuses on innovative methods to target cancer cells effectively.
Latest Patents
Jingjing Zhu's latest patents include groundbreaking technologies aimed at improving cancer detection and treatment. One of his notable inventions is a bi-specific targeting human NKG2DL and CLDN18A2 chimeric antigen receptor cells. This invention provides a preparation method and application for CAR cells that bi-specifically target human NKG2DL and CLDN18A2. The CAR comprises a targeting human NKG2DL antigen domain, an anti-CLDN18A2 antigen binding domain, a hinge domain, a transmembrane domain, and an intracellular T cell signaling domain. This technology can be utilized in methods for detecting cancer presence in mammals and for treating or preventing cancer.
Another significant patent by Zhu is focused on a chimeric antigen receptor cell specifically targeting human Claudin18.2 (CLDN18A2). This invention includes a preparation method and application for CAR cells that recognize CLDN18A2. The extracellular binding region of the CAR is designed to include a protein that specifically recognizes CLDN18A2, with various amino acid sequences. The immune effector cells modified by this CAR can be employed in tumor treatment.
Career Highlights
Jingjing Zhu is currently associated with Nanjing Kaedi Biotherapeutics Ltd., where he continues to innovate in the field of cancer therapeutics. His work has garnered attention for its potential to revolutionize cancer treatment methodologies.
Collaborations
Zhu collaborates with notable colleagues, including Hui Xu and Hongjiu Dai, who contribute to his research and development efforts in biotherapeutics.
Conclusion
Jingjing Zhu's innovative work in developing chimeric antigen receptor cells represents a significant advancement in cancer treatment. His patents reflect a commitment to improving therapeutic options for patients, showcasing the potential of targeted cancer therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile